nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—PSMA1—digestive system—duodenum cancer	0.0526	0.056	CbGeAlD
Bortezomib—PSMD1—pancreas—duodenum cancer	0.0517	0.0551	CbGeAlD
Bortezomib—PSMD2—pancreas—duodenum cancer	0.0458	0.0488	CbGeAlD
Bortezomib—PSMB8—pancreas—duodenum cancer	0.0456	0.0485	CbGeAlD
Bortezomib—CTSG—endocrine gland—duodenum cancer	0.0453	0.0482	CbGeAlD
Bortezomib—PSMA1—endocrine gland—duodenum cancer	0.0435	0.0463	CbGeAlD
Bortezomib—PSMB5—pancreas—duodenum cancer	0.0402	0.0428	CbGeAlD
Bortezomib—PSMD2—digestive system—duodenum cancer	0.0391	0.0417	CbGeAlD
Bortezomib—PSMB1—pancreas—duodenum cancer	0.0352	0.0374	CbGeAlD
Bortezomib—PSMB2—pancreas—duodenum cancer	0.0343	0.0365	CbGeAlD
Bortezomib—PSMD2—endocrine gland—duodenum cancer	0.0323	0.0344	CbGeAlD
Bortezomib—CTSG—lymph node—duodenum cancer	0.0313	0.0333	CbGeAlD
Bortezomib—PSMA1—lymph node—duodenum cancer	0.0301	0.032	CbGeAlD
Bortezomib—PSMB1—digestive system—duodenum cancer	0.03	0.032	CbGeAlD
Bortezomib—PSMB2—digestive system—duodenum cancer	0.0293	0.0312	CbGeAlD
Bortezomib—SLC31A1—digestive system—duodenum cancer	0.0254	0.027	CbGeAlD
Bortezomib—PSMD1—lymph node—duodenum cancer	0.0252	0.0269	CbGeAlD
Bortezomib—PSMB1—endocrine gland—duodenum cancer	0.0248	0.0264	CbGeAlD
Bortezomib—PSMB2—endocrine gland—duodenum cancer	0.0242	0.0258	CbGeAlD
Bortezomib—PSMD2—lymph node—duodenum cancer	0.0224	0.0238	CbGeAlD
Bortezomib—PSMB8—lymph node—duodenum cancer	0.0222	0.0236	CbGeAlD
Bortezomib—SLC31A1—endocrine gland—duodenum cancer	0.021	0.0223	CbGeAlD
Bortezomib—PSMB5—lymph node—duodenum cancer	0.0196	0.0209	CbGeAlD
Bortezomib—PSMB1—lymph node—duodenum cancer	0.0172	0.0183	CbGeAlD
Bortezomib—PSMB2—lymph node—duodenum cancer	0.0167	0.0178	CbGeAlD
Bortezomib—SLC31A1—lymph node—duodenum cancer	0.0145	0.0154	CbGeAlD
Bortezomib—CYP2C19—digestive system—duodenum cancer	0.0107	0.0114	CbGeAlD
Bortezomib—CYP2C19—endocrine gland—duodenum cancer	0.00884	0.00941	CbGeAlD
Bortezomib—CYP1A2—digestive system—duodenum cancer	0.00874	0.0093	CbGeAlD
Bortezomib—CYP1A1—digestive system—duodenum cancer	0.00862	0.00917	CbGeAlD
Bortezomib—CYP2C9—digestive system—duodenum cancer	0.0083	0.00883	CbGeAlD
Bortezomib—CYP2C8—endocrine gland—duodenum cancer	0.00772	0.00821	CbGeAlD
Bortezomib—PTGS1—digestive system—duodenum cancer	0.00757	0.00806	CbGeAlD
Bortezomib—CYP1A2—endocrine gland—duodenum cancer	0.00722	0.00768	CbGeAlD
Bortezomib—CYP1A1—endocrine gland—duodenum cancer	0.00712	0.00758	CbGeAlD
Bortezomib—CYP2C9—endocrine gland—duodenum cancer	0.00685	0.00729	CbGeAlD
Bortezomib—CYP3A4—digestive system—duodenum cancer	0.00633	0.00673	CbGeAlD
Bortezomib—PTGS1—endocrine gland—duodenum cancer	0.00626	0.00666	CbGeAlD
Bortezomib—CYP2D6—digestive system—duodenum cancer	0.00623	0.00662	CbGeAlD
Bortezomib—CYP3A4—endocrine gland—duodenum cancer	0.00523	0.00556	CbGeAlD
Bortezomib—CYP2D6—endocrine gland—duodenum cancer	0.00514	0.00547	CbGeAlD
Bortezomib—CYP1A1—lymph node—duodenum cancer	0.00492	0.00524	CbGeAlD
Bortezomib—PTGS1—lymph node—duodenum cancer	0.00433	0.0046	CbGeAlD
Bortezomib—PSMA1—TCF dependent signaling in response to WNT—MEN1—duodenum cancer	0.00207	0.0344	CbGpPWpGaD
Bortezomib—PSMD1—TCF dependent signaling in response to WNT—MEN1—duodenum cancer	0.00206	0.0342	CbGpPWpGaD
Bortezomib—PSMD2—TCF dependent signaling in response to WNT—MEN1—duodenum cancer	0.00205	0.0341	CbGpPWpGaD
Bortezomib—PSMA1—RNF mutants show enhanced WNT signaling and proliferation—MEN1—duodenum cancer	0.002	0.0333	CbGpPWpGaD
Bortezomib—PSMD1—RNF mutants show enhanced WNT signaling and proliferation—MEN1—duodenum cancer	0.00199	0.0331	CbGpPWpGaD
Bortezomib—PSMD2—RNF mutants show enhanced WNT signaling and proliferation—MEN1—duodenum cancer	0.00198	0.033	CbGpPWpGaD
Bortezomib—PSMA1—Signaling by WNT in cancer—MEN1—duodenum cancer	0.00186	0.0309	CbGpPWpGaD
Bortezomib—PSMD1—Signaling by WNT in cancer—MEN1—duodenum cancer	0.00185	0.0308	CbGpPWpGaD
Bortezomib—PSMD2—Signaling by WNT in cancer—MEN1—duodenum cancer	0.00184	0.0306	CbGpPWpGaD
Bortezomib—PSMB5—TCF dependent signaling in response to WNT—MEN1—duodenum cancer	0.00157	0.0261	CbGpPWpGaD
Bortezomib—PSMB1—TCF dependent signaling in response to WNT—MEN1—duodenum cancer	0.00157	0.0261	CbGpPWpGaD
Bortezomib—PSMB2—TCF dependent signaling in response to WNT—MEN1—duodenum cancer	0.00157	0.0261	CbGpPWpGaD
Bortezomib—PSMB8—TCF dependent signaling in response to WNT—MEN1—duodenum cancer	0.00155	0.0257	CbGpPWpGaD
Bortezomib—PSMA1—Signaling by Wnt—MEN1—duodenum cancer	0.00153	0.0255	CbGpPWpGaD
Bortezomib—PSMD1—Signaling by Wnt—MEN1—duodenum cancer	0.00153	0.0254	CbGpPWpGaD
Bortezomib—PSMD2—Signaling by Wnt—MEN1—duodenum cancer	0.00152	0.0252	CbGpPWpGaD
Bortezomib—PSMB2—RNF mutants show enhanced WNT signaling and proliferation—MEN1—duodenum cancer	0.00152	0.0252	CbGpPWpGaD
Bortezomib—PSMB5—RNF mutants show enhanced WNT signaling and proliferation—MEN1—duodenum cancer	0.00152	0.0252	CbGpPWpGaD
Bortezomib—PSMB1—RNF mutants show enhanced WNT signaling and proliferation—MEN1—duodenum cancer	0.00152	0.0252	CbGpPWpGaD
Bortezomib—PSMB8—RNF mutants show enhanced WNT signaling and proliferation—MEN1—duodenum cancer	0.0015	0.0249	CbGpPWpGaD
Bortezomib—PSMB2—Signaling by WNT in cancer—MEN1—duodenum cancer	0.00141	0.0234	CbGpPWpGaD
Bortezomib—PSMB5—Signaling by WNT in cancer—MEN1—duodenum cancer	0.00141	0.0234	CbGpPWpGaD
Bortezomib—PSMB1—Signaling by WNT in cancer—MEN1—duodenum cancer	0.00141	0.0234	CbGpPWpGaD
Bortezomib—PSMB8—Signaling by WNT in cancer—MEN1—duodenum cancer	0.00139	0.0231	CbGpPWpGaD
Bortezomib—PSMB2—Signaling by Wnt—MEN1—duodenum cancer	0.00116	0.0193	CbGpPWpGaD
Bortezomib—PSMB1—Signaling by Wnt—MEN1—duodenum cancer	0.00116	0.0193	CbGpPWpGaD
Bortezomib—PSMB5—Signaling by Wnt—MEN1—duodenum cancer	0.00116	0.0193	CbGpPWpGaD
Bortezomib—PSMB8—Signaling by Wnt—MEN1—duodenum cancer	0.00115	0.019	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—MEN1—duodenum cancer	0.00055	0.00914	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—MEN1—duodenum cancer	0.000547	0.0091	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—MEN1—duodenum cancer	0.000545	0.00905	CbGpPWpGaD
Bortezomib—PSMA1—Disease—MEN1—duodenum cancer	0.00051	0.00849	CbGpPWpGaD
Bortezomib—PSMD1—Disease—MEN1—duodenum cancer	0.000508	0.00845	CbGpPWpGaD
Bortezomib—PSMD2—Disease—MEN1—duodenum cancer	0.000506	0.00841	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—GAST—duodenum cancer	0.000431	0.00717	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—GAST—duodenum cancer	0.000429	0.00714	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—GAST—duodenum cancer	0.000427	0.0071	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—MEN1—duodenum cancer	0.000417	0.00693	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—MEN1—duodenum cancer	0.000417	0.00693	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—MEN1—duodenum cancer	0.000417	0.00693	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—MEN1—duodenum cancer	0.000411	0.00683	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—SCT—duodenum cancer	0.000409	0.0068	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—SCT—duodenum cancer	0.000407	0.00677	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—SCT—duodenum cancer	0.000405	0.00673	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MEN1—duodenum cancer	0.000387	0.00643	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MEN1—duodenum cancer	0.000387	0.00643	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MEN1—duodenum cancer	0.000387	0.00643	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MEN1—duodenum cancer	0.000381	0.00634	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MEN1—duodenum cancer	0.000357	0.00594	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MEN1—duodenum cancer	0.000356	0.00591	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MEN1—duodenum cancer	0.000354	0.00589	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—GAST—duodenum cancer	0.000327	0.00543	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—GAST—duodenum cancer	0.000327	0.00543	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—GAST—duodenum cancer	0.000327	0.00543	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—GAST—duodenum cancer	0.000322	0.00536	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SCT—duodenum cancer	0.00031	0.00515	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SCT—duodenum cancer	0.00031	0.00515	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SCT—duodenum cancer	0.00031	0.00515	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SCT—duodenum cancer	0.000306	0.00508	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—SST—duodenum cancer	0.000296	0.00492	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—SST—duodenum cancer	0.000294	0.00489	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—SST—duodenum cancer	0.000293	0.00487	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MEN1—duodenum cancer	0.000271	0.0045	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MEN1—duodenum cancer	0.000271	0.0045	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MEN1—duodenum cancer	0.000271	0.0045	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MEN1—duodenum cancer	0.000267	0.00444	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SST—duodenum cancer	0.000224	0.00372	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SST—duodenum cancer	0.000224	0.00372	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SST—duodenum cancer	0.000224	0.00372	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SST—duodenum cancer	0.000221	0.00367	CbGpPWpGaD
